An executive from pharmaceutical company GSK must choose how much to incorporate Sirtris, a recently acquired biotechnology firm. Moncef Slaoui, GSK's International head of R&D, championed the acquisition of Sirtris to get access to its possibly groundbreaking science. Slaoui must balance the need to recoup shareholder value after paying a two times premium for Sirtris with his want to retain Christoph Westphal, Sirtris's co-founder and CEO, and other key people at the business.
The case also investigate the perspective of Christoph Westphal on the early challenges of the integration and the impact GSK was having on Sirtris. Can be used in conjunction with another case that focuses on the business model of Sirtris.
PUBLICATION DATE: April 21, 2009 PRODUCT #: 809026-HCB-ENG
This is just an excerpt. This case is about INNOVATION & ENTREPRENEURSHIP
Related Case Solutions & Analyses:
TripIt: The Travelers Agent
Pfizer Pharmaceuticals: Green Chemistry Innovation and Business Strategy
Technology Transfer at U.S. Universities
Z Corp.
Note on Strategic Alliances
Medical Foods Inc.
The Mosquito Network: Collaborative Entrepreneurship in the Fight to Eliminate Malaria Deaths (B)
Entrepreneurial Sales and Marketing Vignettes
Alloy.com
Starbucks Green Policy
